As shown already similarly for HD and SCA3, our newly established ATXN2 immunoassay specifically quantifies soluble polyQ-expanded ATXN2 if the polyQ-specific antibody MW1 is combined with an ATXN2-specific donor antibody [44]. Here, ATXN3 is linked to Huntington disease.